Genotyping of cytochrome P450 isoform genes is useful for forensic identification of cadaver

Legal Medicine

Volumn 5, Issue 3, 2003, Pages 132-138

  Ogawa, Kento ^a   Suno, Manabu ^a   Shimizu, Keiko ^a   Yoshida, Masatsugu ^a   Awaya, Toshio ^a   Matsubara, Kazuo ^a   Shiono, Hiroshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

DNA polymorphisms; P450 (CYP); Personal identification

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DNA; ISOPROTEIN;

ARTICLE; CADAVER; CONTROLLED STUDY; DNA FLANKING REGION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; FORENSIC IDENTIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPAN; NORMAL HUMAN; OUTCOMES RESEARCH; POPULATION RESEARCH; SEQUENCE HOMOLOGY;

EID: 0242636920     PISSN: 13446223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1344-6223(03)00055-5     Document Type: Article

References (21)

1. Evans WE, Relling MV. Pharmacogenetics: Translating functional genomics into rational therapeutics. Science 1999;286:487-91.
2. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 1998;287:791-9.
3. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998;28:1203-53.
4. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413-580.
5. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. J Biochem 1999;125:803-8.
6. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999;65:570-5.
7. Tsutsumi M, Takada A, Wang J-S. Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease. Gastroenterology 1994;107:1430-5.
8. Kimura M, Ieri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 1998;20:243-7.
9. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661-6.
10. Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 1996;6:265-7.
11. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
12. Steen VM, Andreasen OA, Daly AK, Tefre T, Børresen A-L, Idle JR, Gulbrandsen A-K. Detection of the poor metabolizer-associated CYP2D6(D) gene detection allele by long-PCR technology. Pharmacogenetics 1995;5:215-23.
13. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-65.
14. Wang S-L, Huang J-D, Lai M-D, Tsai J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995;5:37-42.
15. Suno M, Awaya T, Ogawa K, Ohtaki K, Chiba K, Hayase N, Matsubara K. A wax-mediated hot-start polymerase chain reaction improves the genotyping of CYP2C9*1 and *3 alleles. Jpn J Clin Pharmacol Ther 2002;33:215-8.
16. De Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
17. De Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
18. Oscarson M, Ingelman-Sundberg M, Daly AK, Nebert DW, Brockmöller J, Eichelbaum M, Garte S, Goldstein JA, Gonzalez FJ, Kadlubar FF, Kamataki T, Meyer UA, Nelson DR, Waterman MR, Wedell A, Zanger UM. Human cytochrome P450 (CYP) alleles [web site]. 2000;
19. Veronese ME, Doecke CJ, Mackenzie PI, Mcmanus ME, Miners JO, Rees DLP, Gasser R, Meyer UA, Birkett DJ. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993;289:533-8.
20. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang Z-Y, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
21. Mamiya K, Ieiri I, Miyahara S, Imai J, Furuumi H, Fukumaki Y, Ninomiya H, Tashiro N, Yamada H, Higuchi S. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients. Pharmacogenetics 1998;8:87-90.